Banner

World Health Assembly endorses new plan to increase global access to vaccines

World Health OrganizationMinisters of Health from 194 countries at the Sixty-fifth World Health Assembly endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

The GVAP was coordinated by the Decade of Vaccines Collaboration, a group of leading international vaccine experts, and represents the collective vision of hundreds of global health stakeholders to extend the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.

Currently, four out of every five children receive at least a basic set of vaccinations during infancy that allow them to lead healthy, productive lives. However, this means 20 percent of children still do not benefit from basic immunization.

This comprehensive plan involves four mutually reinforcing goals: strengthening routine immunization to meet vaccination coverage targets; accelerating control of vaccine-preventable diseases with polio eradication as the first milestone; introducing new and improved vaccines; and spurring research and development for the next generation of vaccines and technologies. The plan is expected to reduce global childhood mortality, surpassing the targets of the United Nations Millennium Development Goal 4.

"The Global Vaccine Action Plan focuses on the health needs of people at all stages of life," said Dr. Flavia Bustreo, Assistant Director-General for Family, Women's and Children's Health of the World Health Organization. "The plan promotes greater coordination and synergies between immunization and other child, adolescent and reproductive health interventions leading to healthier communities everywhere."

"While immunization already prevents millions of deaths and uncounted illness, we cannot rest until life-saving, cost-effective vaccine technology reaches people in every community and every country through this global plan," said Dr. Ciro de Quadros, Executive Vice President of the Sabin Vaccine Institute and co-chair of the Decade of Vaccines Collaboration's Steering Committee.

Following the approval by the World Health Assembly, the GVAP will be adapted for implementation at the regional and country level. Country involvement in this process reinforces a key tenet of the GVAP, which is to increase national ownership of immunization programs. The collaboration will also establish a monitoring and evaluation framework and finalize estimates for funding needs as well as potential cost savings.

"By supporting countries to strengthen their health systems and introduce powerful vaccines that prevent the biggest killers of children, we can have a dramatic impact on the lives of millions of people. We need to work together to make the vision of the Global Vaccine Action Plan a reality, and I am proud that GAVI will play its part in this," said Dr. Seth Berkley, CEO of the GAVI Alliance.

Innovation is a guiding principle of the GVAP beyond the vaccines themselves. The plan identifies priorities for improving program efficiency and increasing vaccine coverage. This includes the use of modern communication technologies for immunization programs; research to understand the cultural, economic and organizational determinants of immunization; and the development of diagnostic tools for conducting surveillance in low-income countries. The plan also focuses on building capacity and human resources in low- and middle-income countries to conduct research and development and operational research.

"We know vaccines work to save and improve lives," said Dr. Chris Elias, president of the global development program at the Bill & Melinda Gates Foundation. "We must urgently work to reach all children with the vaccines they need."

Lending further support to the Decade of Vaccines, world health ministers also endorsed a resolution declaring polio a global public health emergency. The eradication of polio is a critical step in protecting all children from vaccine-preventable diseases and is an important early milestone in the Decade of Vaccines.

A large and diverse group of stakeholders representing 290 organizations - including representatives and elected officials, health professionals, academics, manufacturers, global agencies, development partners, civil society, media and the private sector in more than 140 countries - contributed their expertise to the development of the GVAP in a year-long consultation process.

"It is unacceptable that children are still dying from diseases that are preventable with existing vaccines," said Dr. Abdul Majeed Siddiqi, Head of Mission for HealthNet TPO in Afghanistan and Pakistan and Chair of the GAVI Civil Society Steering Committee. "This is an actionable plan across the discovery, development and delivery of vaccines - now we must all do our part to make it happen."

Key representatives from the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation, the GAVI Alliance, the U.S. National Institute of Allergy and Infectious Diseases and the African Leaders Malaria Alliance had central roles in the DoV Collaboration Leadership Council and working groups.

About the Decade of Vaccines Collaboration
The Decade of Vaccines Collaboration is an effort that has brought together diverse organizations, experts, scientists and governments to develop a Global Vaccine Action Plan that will stimulate the discovery, development, and delivery of lifesaving vaccines, to achieve the vision of a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases. Its mission is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.

About the World Health Organization
The World Health Organization, WHO, is the directing and coordinating authority on international health within the United Nations. With offices in over 147 countries, WHO is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. In addition to medical doctors, public health specialists, scientists and epidemiologists, WHO staff include people trained to manage administrative, financial, and information systems, as well as experts in the fields of health statistics, economics and emergency relief.

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Banner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

News in Pictures

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/9445461331.jpg

Abbott Launches New Psoriasisanswers.com Web site

August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/399322AstraZeneca_Headquarters.jpg

AstraZeneca Headquarters, London

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/280148roche_basel.jpg

Site Roche Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/390839Gehry_Novartis.jpg

Gehry building, Novartis headquarters in Basel, Switzerland

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/240209GSK_Corporate.jpg

GSK Corporate HQ

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/200324sanofi_avenits.jpg

Sanofi-aventis Group head office

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/964792Boehringer_Ingelheim_Center.jpg

Boehringer Ingelheim Center, Ingelheim, Germany

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more

http://worldpharmanews.com/components/com_gk3_photoslide/thumbs_big/164840Novo_Nordisk.jpg

Novo Nordisk's corporate headquarters in Bagsværd, Denmark

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more

Be on top of World Pharma News
Want to place your Ads or News at the top of World Pharma News? Contact us now!